Literature DB >> 8691841

Totally implanted device for long-term intravenous chemotherapy: experience in 123 adult patients with solid neoplasms.

J Puig-la Calle1, S López Sánchez, E Piedrafita Serra, L Allende Honorato, V Artigas Raventós, J Puig la Calle.   

Abstract

Vascular access in patients receiving prolonged chemotherapy is a difficult problem. This led to the introduction of a totally implanted device. We intend to assess the efficacy of this device in a subset of oncologic patients. Between May 1989 and November 1992, 129 devices were placed in 123 adult patients with solid neoplasms. Most of the catheters were inserted by cut-down of the external jugular vein. Follow-up period ranged from 28 to 70 months. Early complications occurred in 4 of 129 implants, all in percutaneously inserted catheters. Infection was the most frequent late complication. By March 1995, 113 devices had been removed, 15 (13.3%) because of complications. Mean life of the explanted systems was 512 days. Totally implanted devices provide safe and efficient long-term venous access. Implantation should be performed by experienced surgeons, by cut-down whenever possible. Infection is the most serious complication and may be prevented by careful management.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8691841     DOI: 10.1002/(SICI)1096-9098(199608)62:4<273::AID-JSO9>3.0.CO;2-3

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  5 in total

Review 1.  Systematic review: malfunction of totally implantable venous access devices in cancer patients.

Authors:  Godelieve Alice Goossens; Marguerite Stas; Martine Jérôme; Philip Moons
Journal:  Support Care Cancer       Date:  2011-05-10       Impact factor: 3.603

2.  Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports.

Authors:  Jo Caers; Christel Fontaine; Vincent Vinh-Hung; Johan De Mey; Gerrit Ponnet; Chris Oost; Jan Lamote; Jacques De Greve; Benjamin Van Camp; Patrick Lacor
Journal:  Support Care Cancer       Date:  2004-11-05       Impact factor: 3.603

3.  Analysis of risk factors for central venous port failure in cancer patients.

Authors:  Ching-Chuan Hsieh; Hsu-Huei Weng; Wen-Shih Huang; Wen-Ke Wang; Chiung-Lun Kao; Ming-Shian Lu; Chia-Siu Wang
Journal:  World J Gastroenterol       Date:  2009-10-07       Impact factor: 5.742

4.  External jugular vein cutdown approach for chronic indwelling central venous access in cancer patients: A potentially useful alternative.

Authors:  Stephen P Povoski
Journal:  World J Surg Oncol       Date:  2004-04-16       Impact factor: 2.754

5.  Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer.

Authors:  H Y Sheikh; J W Valle; T Waddell; K Palmer; G Wilson; A Sjursen; O Craven; R Swindell; M P Saunders
Journal:  Br J Cancer       Date:  2008-08-19       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.